Certara (NASDAQ:CERT) Releases FY 2026 Earnings Guidance

Certara (NASDAQ:CERT) updated its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 0.350-0.410 for the period, compared to the consensus estimate of 0.360. The company issued revenue guidance of $395.0 million-$405.0 million, compared to the consensus revenue estimate of $398.9 million.

Analyst Upgrades and Downgrades

CERT has been the topic of a number of research reports. Weiss Ratings restated a “sell (e+)” rating on shares of Certara in a research report on Friday, May 29th. Stephens dropped their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a research note on Tuesday, May 12th. Robert W. Baird decreased their target price on shares of Certara from $7.00 to $6.00 and set a “neutral” rating on the stock in a research note on Tuesday, May 12th. Craig Hallum decreased their target price on Certara from $10.00 to $8.00 and set a “hold” rating for the company in a report on Tuesday, May 12th. Finally, KeyCorp cut their target price on shares of Certara from $10.00 to $8.00 and set an “overweight” rating on the stock in a research note on Monday, April 13th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $8.85.

Certara Trading Up 2.7%

Certara stock opened at $6.73 on Thursday. The company has a market cap of $1.05 billion, a P/E ratio of -67.30 and a beta of 1.46. Certara has a 52-week low of $4.45 and a 52-week high of $13.88. The business has a 50-day simple moving average of $5.60 and a two-hundred day simple moving average of $6.86. The company has a quick ratio of 1.88, a current ratio of 1.88 and a debt-to-equity ratio of 0.28.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Monday, May 11th. The company reported $0.09 EPS for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The firm had revenue of $106.92 million for the quarter, compared to the consensus estimate of $106.13 million. Certara had a negative net margin of 3.60% and a positive return on equity of 3.52%. Certara’s quarterly revenue was up .8% on a year-over-year basis. During the same period in the previous year, the company posted $0.14 earnings per share. Certara has set its FY 2026 guidance at 0.350-0.410 EPS. Analysts predict that Certara will post 0.24 EPS for the current year.

Hedge Funds Weigh In On Certara

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Wasatch Advisors LP boosted its stake in shares of Certara by 45.7% during the 2nd quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock worth $158,335,000 after acquiring an additional 4,244,230 shares in the last quarter. Deerfield Management Company L.P. increased its holdings in shares of Certara by 71.7% during the 3rd quarter. Deerfield Management Company L.P. now owns 6,739,537 shares of the company’s stock worth $82,357,000 after buying an additional 2,813,438 shares during the last quarter. Ameriprise Financial Inc. increased its holdings in Certara by 27.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after purchasing an additional 1,165,064 shares during the last quarter. UBS Group AG raised its holdings in Certara by 106.3% in the third quarter. UBS Group AG now owns 1,651,955 shares of the company’s stock valued at $20,187,000 after acquiring an additional 851,249 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. lifted its position in Certara by 580,097.9% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 829,683 shares of the company’s stock valued at $7,310,000 after acquiring an additional 829,540 shares during the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.